APLS250117P48000
- 0.00
- 0.000.00%
Apellis Pharmaceuticals Newsroom
Wedbush Raises Price Target on Apellis Pharmaceuticals to $30 From $25, Keeps Neutral Rating
RBC Capital Reiterates Sector Perform on Apellis Pharmaceuticals, Maintains $26 Price Target
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $31 to $47
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $32 to $60
Apellis Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.
Apellis Pharmaceuticals Analyst Ratings
Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $47
Buy Rating Maintained for Apellis Pharmaceuticals: Strategic Market Position and Growth Potential Justify Price Objective
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $47
Goldman Sachs Downgrades Apellis Pharmaceuticals to Neutral From Buy, $36 Price Target
Apellis Pharmaceuticals Price Target Announced at $36.00/Share by Goldman Sachs
Apellis Pharmaceuticals Analyst Ratings
Goldman Sachs Downgrades Apellis Pharmaceuticals(APLS.US) to Hold Rating
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $47
Buy Rating for Apellis Pharmaceuticals: Promising Growth Potential of Syfovre in Geographic Atrophy Market
RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals Initiated at Equal-Weight by Morgan Stanley
Apellis Pharmaceuticals Analyst Ratings